Evidence map›Paper›PMID 21163373›Full record

ArticleAmerican journal of ophthalmology2011

Appropriate use and reporting of uncontrolled case series in the medical literature.

John H Kempen

Abstract read
In one paragraph

Article in American journal of ophthalmology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Sensorimotor Perceptive Rehabilitation Integrated (SPRInt) program: exercises with augmented movement feedback associated to botulinum neurotoxin in idiopathic cervical dystonia-an observational study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020
    Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Can We Have Guidelines or Just Guidance for Rare Fungal Infections?Journal of fungi (Basel, Switzerland) · 2025
    Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Co-occurrence ofAmerican journal of ophthalmology case reports · 2025
    Article
  17. Clinical factors predicting nemolizumab response in atopic dermatitis.The journal of allergy and clinical immunology. Global · 2025
    Article
  18. Observational
  19. Article
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

John H KempenDepartment of Ophthalmology/Scheie Eye Institute, the Center for Clinical Epidemiology and Biostatistics, The University of Pennsylvania School of Medicine, Philadelphia, 19104, USA. john.kempen@uphs.upenn.edu

Funding

Long-term Follow-up of the Systemic Immunosuppressive Therapy for Eye Diseases CohortR01EY014943 · NEI · UNIVERSITY OF PENNSYLVANIA · PI KEMPEN, JOHN H · 2004 to 2025
$8.1M
Complications of Immunosupression for Eye DiseasesR56EY014943 · NEI · UNIVERSITY OF PENNSYLVANIA · PI KEMPEN, JOHN H · 2009 to 2009
$159k
NEI NIH HHS R01 EY014943NEI NIH HHS R56 EY014943
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Case-Control StudiesData Interpretation, StatisticalPublicationsResearch DesignBiomedical ResearchEpidemiologic MethodsHumans

Identifiers

PMID21163373
PMCPMC3052978

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.